Insider Selling: Alumis (NASDAQ:ALMS) Insider Sells 2,596 Shares

Alumis Inc. (NASDAQ:ALMS) insider David Goldstein sold 2,596 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $68,456.52. Following the completion of the transaction, the insider owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. The trade was a 7.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alumis Stock Performance

Shares of NASDAQ ALMS remained flat at $27.12 during mid-day trading on Wednesday. The company had a trading volume of 629,130 shares, compared to its average volume of 2,037,268. The company has a market capitalization of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69. The stock has a 50 day moving average of $25.26 and a two-hundred day moving average of $25.20. Alumis Inc. has a one year low of $3.76 and a one year high of $31.35.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. Analysts forecast that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Institutional Trading of Alumis

A number of institutional investors and hedge funds have recently bought and sold shares of ALMS. Russell Investments Group Ltd. lifted its stake in shares of Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares in the last quarter. New York State Common Retirement Fund lifted its position in Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after acquiring an additional 7,467 shares in the last quarter. KBC Group NV purchased a new stake in Alumis during the 1st quarter valued at $42,000. Strs Ohio increased its holdings in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Alumis by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares in the last quarter.

Wall Street Analysts Forecast Growth

ALMS has been the topic of several research reports. Wells Fargo & Company boosted their price objective on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. HC Wainwright reiterated a “neutral” rating and set a $25.00 target price on shares of Alumis in a report on Monday. Chardan Capital boosted their price target on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Guggenheim upped their price target on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.